[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"volatile-organic-compound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:volatile-organic-compound":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100611099","early-phase-1-b-glucancer2--a-pilot-study-evaluating-a-new-method-for-cancer-detection-by-measuring-the-activity-of-different-glycosidase-enzymes-in-the-plasma-of-patients-with-a-localized-cancer-100611099",false,"NCT07236177","B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.","Evaluation of a New Method for Detecting Cancer Pathologies by Measuring the Activity of Different Glycosidases in Plasma in Patients With Localized Cancer - Pilot Study: B-GLUCANCER2","B-GLUCANCER2","Inclusion Criteria:\n\n* Group 1: 40 patients with definitively diagnosed, untreated, localized solid breast cancer referred for initial surgical treatment.\n\nGroup 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment.\n\nGroup 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment.\n\nGroup 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer.\n\nExclusion Criteria:\n\n* Refusal to participate in the research.\n* Patients benefiting from enhanced protection, namely: minors, pregnant\u002Fbreastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection\n\nSpecific criteria for groups 1, 2, and 3:\n\n* Cancer patients undergoing oncological treatment.\n* Cancer not proven by anatomopathological examination.",true,"ALL","18 Years",{"count":21,"type":22},220,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The goal of this clinical trial is to develop a new cancer diagnostic and prognostic tool based on the dynamic and non-invasive detection of an exogenous volatile molecule, i.e., ethanol, from patients' samples.\n\nPatients' blood plasma will be analyzed with a mixture of volatile organic compound-based probes, each targeting a specific glycosidase. The presence of a given glycosidase in a blood sample would thus be revealed by the detection of an ethanol isotope in the gas phase.\n\n3 groups of patients with localized cancer (breast, prostate, pancreas) will be enrolled, as well as 1 group of patient without any cancer (control group).\n\nFor the patients, two 5ml plasma samples will be collected, one before and one after surgery for localized cancers. For healthy volunteers, only one 5ml plasma sample will be collected.\n\nThe primary objective will be to compare the levels of glycosidases measured in the blood of patients followed for localized cancer and referred for first surgery compared to control patients without cancer.",[28,29,30,31,32,33,34],"Breast Cancer","Pancreatic Cancer","Pulmonary Cancer","Volatile Organic Compound","Glycosidase Activity","Probes","Tumor Markers, Biological",[36,37,38,39,40,41],"breast cancer","pancreatic cancer","pulmonary cancer","volatile organic compounds","glycosidase activity","localized cancer","RECRUITING","2026-02-04",{"date":45,"type":46},"2026-02-05","ACTUAL",{"date":48,"type":46},"2026-02-03",{"date":50,"type":22},"2028-03-03",{"name":52,"class":53},"Poitiers University Hospital","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":75,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100612988","augmented-response-of-volatile-biomarkers-in-the-assessment-of-oesophagogastric-cancer-aroma2-100612988","NCT07260734","AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","AROMA2","Inclusion Criteria:\n\n* Aged ≥ 18 years old.\n* Participants referred from primary care according to the urgent suspected cancer referral guidelines for potential underlying oesophagogastric cancer a for the reference test (described below).\n* Willing and able to provide informed written consent to take part in study.\n\nExclusion Criteria:\n\n* Previous oesophageal or gastric resection\n* History of cancer within three years (other than non-melanoma skin cancers)\n* Co-morbidities preventing breath collection\n* Pregnant participants\n* Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid\n* Unable or unwilling to provide informed written consent.",{"count":63,"type":22},6000,"3 Months","OBSERVATIONAL","Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut.\n\nThe proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.",[68,69,70,71,72,73,74,31],"OESOPHAGO-GASTRIC CARCINOMA","Oesophageal Adenocarcinoma","Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","Oesophageal Cancer Nos","Oesophageal Cancer","Oesophageal Junction Cancer","Breath Tests",[76,77,78,79,80,81,82,83],"Oesophageal adenocarcinoma","Gastric adenocarcinoma","Breath testing","Microbiome","Augmentation","Volatile Organic Compounds","Volatilomics","Breathomics","NOT_YET_RECRUITING","2025-11-21",{"date":87,"type":46},"2025-12-03",{"date":89,"type":22},"2025-12-01",{"date":91,"type":22},"2028-11-01",{"name":93,"class":53},"Imperial College London",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100583529","rapid-diagnostic-technology-for-augib-based-on-analysis-of-vocs-in-exhaled-breath-100583529","NCT06877507","Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath","Rapid Diagnostic Technology for Acute Upper Gastrointestinal Bleeding Based on Analysis of Volatile Organic Compounds (VOCs) in Exhaled Breath","VOCsAUGIB","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Clinical suspicion of AUGIB (e.g., hematemesis, melena);\n3. Fasting ≥4 hours;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Severe pulmonary dysfunction or recent lung infection (within 1 week);\n2. Cardiac\u002Frenal failure or disseminated intravascular coagulation;\n3. Contraindications to endoscopy;\n4. High-risk conditions (e.g., massive ascites);\n5. Alcohol consumption within 24 hours;\n6. Pregnancy.",{"count":103,"type":22},200,"This study aims to develop a non-invasive and rapid diagnostic technology for acute upper gastrointestinal bleeding (AUGIB) by analyzing volatile organic compounds (VOCs) in exhaled breath. Clinically confirmed patients will be divided into three groups (no bleeding, minor bleeding, major bleeding) based on endoscopic findings. VOC profiles will be analyzed to construct a predictive model, validated for sensitivity and specificity (both targets ≥0.7). This approach addresses the limitations of endoscopy in emergency or resource-limited settings, improving diagnostic efficiency and reducing mortality.",[31,106],"Gastrointestinal Hemorrhage",[31,108,109],"Acute Upper Gastrointestinal Bleeding","Exhaled Breath","2025-03-10",{"date":112,"type":46},"2025-03-14",{"date":114,"type":22},"2025-03-20",{"date":116,"type":22},"2025-07-20",{"name":118,"class":53},"Beijing 302 Hospital"]